Positron emission tomography in mantle cell lymphoma.
Mantle cell lymphoma (MCL) is a rare but aggressive non-Hodgkin lymphoma subtype with a poor prognosis; most patients relapse despite initial response to therapy. Response was traditionally evaluated by computed tomography (CT), but the introduction of [(18)F]Fluorine-Deoxyglucose Positron Emission Tomography (PET) changed response assessment in aggressive lymphoma. However, the value of PET-evaluation in MCL has not been studied yet. Therefore, PET- and CT-findings were investigated in 37 patients with MCL (239 scans) and categorised following standardised response criteria for CT-evaluation (IWC-criteria), PET-evaluation (EORTC-criteria) and combined PET/CT-evaluation (IWC + PET-criteria). FDG-PET showed a high sensitivity for the detection of deposits of MCL and a higher FDG-uptake was shown in patients with the more aggressive blastoid-variant of MCL versus common MCL. However, routine use of PET for end-of-treatment response assessment in MCL cannot be recommended because CT- and PET-based designation systems had equivalent prognostic value. PET-based end-of-treatment response assessment only provided additional information over CT-based response assessment in a subpopulation of patients with highly FDG-avid MCL. PET allowed early detection of preclinical relapse during post-therapy surveillance, but the therapeutic consequences of such information are currently unclear.
Brepoels
Lieselot
L
Department of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University Leuven, Leuven, Belgium. lieselot.brepoels@uz.kuleuven.ac.be
Stroobants
Sigrid
S
De Wever
Walter
W
Dierickx
Daan
D
Vandenberghe
Peter
P
Thomas
Jose
J
Mortelmans
Luc
L
Verhoef
Gregor
G
De Wolf-Peeters
Christiane
C
D000328:Adult; D000368:Aged; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000000981:diagnostic imaging* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000175:diagnosis; D049268:Positron-Emission Tomography / Q000592:standards*; D011379:Prognosis; D014057:Tomography, X-Ray Computed / Q000592:standards; D016896:Treatment Outcome
D019788:Fluorodeoxyglucose F18